Resource Summary Report

Generated by dkNET on Sep 1, 2026

beta-Catenin Antibody (Carboxy-terminal Antigen)

RRID:AB_10695312
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9587, RRID:AB_10695312

Antibody Information

URL: http://antibodyregistry.org/AB_10695312

Proper Citation: Cell Signaling Technology Cat# 9587, RRID:AB_10695312

Target Antigen: beta-Catenin (Carboxy-terminal Antigen)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P, IHC-F, ChIP. Consolidation on 11/2018: AB_10695312, AB_10827874, AB_490892.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: beta-Catenin Antibody (Carboxy-terminal Antigen)

Description: This polyclonal targets beta-Catenin (Carboxy-terminal Antigen)

Target Organism: b, c, dg, rat, porcine, h, canine, hr, m, horse, mouse, r, pg, x, bovine, human, mk

Antibody ID: AB_10695312

Vendor: Cell Signaling Technology

Catalog Number: 9587

Record Creation Time: 20250820T022855+0000

Record Last Update: 20250820T134227+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for beta-Catenin Antibody (Carboxy-terminal Antigen).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Shao YY, et al. (2025) Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma. Biology direct, 20(1), 49.

Mosialou I, et al. (2025) A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. Cancer cell, 43(6), 1007.

Zhang W, et al. (2024) Decreased extrasynaptic ?-GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease. British journal of pharmacology, 181(20), 3944.

Zhang M, et al. (2022) CDK14 inhibition reduces mammary stem cell activity and suppresses triple negative breast cancer progression. Cell reports, 40(11), 111331.

Favaloro F, et al. (2022) miR-17?92 exerts stage-specific effects in adult V-SVZ neural stem cell lineages. Cell reports, 41(10), 111773.

Pan R, et al. (2022) RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation. iScience, 25(10), 105184.

Lee R, et al. (2022) Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer. Cancer discovery, 12(7), 1702.

Zhao D, et al. (2021) Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation. Cell chemical biology, 28(8), 1235.

Zhou X, et al. (2019) YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis. Cell reports, 27(4), 1176.

Kim MJ, et al. (2018) PAF-Myc-Controlled Cell Stemness Is Required for Intestinal Regeneration and Tumorigenesis. Developmental cell, 44(5), 582.